Literature DB >> 2328748

N-acetylation phenotyping with sulphadimidine in a Turkish population.

A Bozkurt1, N E Basci, S Kalan, M Tuncer, S O Kayaalp.   

Abstract

The distribution of acetylator phenotypes was studied in 244 unrelated Turkish subjects. Sulphadimidine and its acetylated metabolite were measured in 6 h plasma and 0-6 h urine samples after an oral dose of 10 mg/kg. Subjects with 37.5% or less acetylsulphadimidine in plasma were regarded as slow acetylators and the others as rapid acetylators. The mean plasma concentration of acetylsulphadimidine was about 2.5-times lower in slow acetylators. Urinary excretion of total sulphadimidine (free + acetylated) was also significantly lower in slow acetylators compared to rapid acetylators. The frequency of slow acetylators was 60.7% in the population (95% confidence interval 54.3% to 66.8%). Sulphadimidine acetylation showed no variation due to sex, age, body weight or pre-existing disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328748     DOI: 10.1007/bf00314803

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

2.  Hepatic drug acetylation and oxidation: effects of aging in man.

Authors:  F Farah; W Taylor; M D Rawlins; O James
Journal:  Br Med J       Date:  1977-07-16

3.  An improved and simplified method of detecting the acetylator phenotype.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1969-12       Impact factor: 6.318

4.  Determination of the acetylator phenotype in a Turkish population.

Authors:  S Sardas; A E Karakaya; I Cok
Journal:  Clin Genet       Date:  1986-02       Impact factor: 4.438

5.  [The importance of estimating the individual acetylation rate in modern tuberculosis treatment].

Authors:  S Duru
Journal:  Mikrobiyol Bul       Date:  1979-01       Impact factor: 0.622

Review 6.  N-acetylation pharmacogenetics.

Authors:  W W Weber; D W Hein
Journal:  Pharmacol Rev       Date:  1985-03       Impact factor: 25.468

7.  Acetylator phenotypes: effect of age.

Authors:  B Gachályi; A Vas; P Hajós; A Káldor
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Polymorphic N-acetylation of a caffeine metabolite.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

9.  Polymorphic acetylation of sulphadimidine in normal and uraemic man.

Authors:  T Talseth; K H Landmark
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

Review 10.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

View more
  1 in total

1.  Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.

Authors:  Etienne Patin; Luis B Barreiro; Pardis C Sabeti; Frédéric Austerlitz; Francesca Luca; Antti Sajantila; Doron M Behar; Ornella Semino; Anavaj Sakuntabhai; Nicole Guiso; Brigitte Gicquel; Ken McElreavey; Rosalind M Harding; Evelyne Heyer; Lluis Quintana-Murci
Journal:  Am J Hum Genet       Date:  2006-01-13       Impact factor: 11.025

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.